Posterior Atrophy Predicts Time to Dementia in Patients with Amyloid-positive Mild Cognitive Impairment

Overview

Journal Alzheimers Res Ther

Date 2017 Dec 17

PMID 29246250

Citations 9

Authors

Jung-Min Pyun

Young Ho Park

Hang-Rai Kim

Jeewon Suh

Min Ju Kang

Beom Joon Kim

Young Chul Youn

Jae-Won Jang

SangYun Kim

Affiliations

Soon will be listed here.

Abstract

Background: In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although posterior atrophy (PA) is a well-known neurodegenerative biomarker of Alzheimer's disease, little is known about PA as a predictor in patients with amyloid-positive MCI.

Methods: We included 258 patients with amyloid-positive MCI with at least one follow-up visit, and who had low cerebrospinal fluid (CSF) β-amyloid concentration. Data were obtained from the Alzheimer's Disease Neuroimaging Initiative study. We assessed PA and MTA on magnetic resonance imaging (MRI) using visual rating scales and retrospectively determined progression to dementia during the follow-up period of up to 3 years (median 24 months). The Cox proportional hazards model was used to analyze hazard ratios (HRs) of PA and MTA for disease progression. Additionally, subjects were divided into four groups according to brain atrophy pattern (no atrophy, MTA only, PA only, both MTA and PA), and HRs for disease progression were compared with the no atrophy reference group. Analyses were conducted with and without adjustment for CSF phosphorylated tau (p-tau) and baseline demographics.

Results: A total of 123 patients (47.7%) showed MTA and 174 patients (67.4%) showed PA. Of the total cohort, 139 cases (53.9%) progressed to dementia. PA and MTA were associated with an increased risk for progression to dementia (HR 2.244, 95% confidence interval (CI) 1.497-3.364, and HR 1.682, 95% CI 1.203-2.352, respectively). In the analysis according to atrophy pattern, HR (95% CI) for progression was 2.998 (1.443-6.227) in the MTA only group, 3.126 (1.666-5.864) in the PA only group, and 3.814 (2.045-7.110) in both MTA and PA group. These results remained significant after adjustment.

Conclusions: In patients with amyloid-positive MCI, PA could predict progression to dementia independently of MTA.

Citing Articles

Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes.

Pyun J, Park Y, Kang M, Kim S Alzheimers Res Ther. 2024; 16(1):210.

PMID: 39358798 PMC: 11448210. DOI: 10.1186/s13195-024-01580-y.

The impact of medial temporal and parietal atrophy on cognitive function in dementia.

Susianti N, Prodjohardjono A, Vidyanti A, Setyaningsih I, Gofir A, Setyaningrum C Sci Rep. 2024; 14(1):5281.

PMID: 38438548 PMC: 10912680. DOI: 10.1038/s41598-024-56023-3.

Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review.

Garcia M, Leadley R, Ross J, Bozeat S, Redhead G, Hansson O J Alzheimers Dis Rep. 2024; 8(1):203-240.

PMID: 38405341 PMC: 10894607. DOI: 10.3233/ADR-230045.

Consensus on rapid screening for prodromal Alzheimer's disease in China.

Huang L, Li Q, Lu Y, Pan F, Cui L, Wang Y Gen Psychiatr. 2024; 37(1):e101310.

PMID: 38313393 PMC: 10836380. DOI: 10.1136/gpsych-2023-101310.

The role of magnetic resonance imaging in the diagnosis and prognosis of dementia.

Zivanovic M, Aracki Trenkic A, Milosevic V, Stojanov D, Misic M, Radovanovic M Biomol Biomed. 2022; 23(2):209-224.

PMID: 36453893 PMC: 10113939. DOI: 10.17305/bjbms.2022.8085.

References

Qi Z, Wu X, Wang Z, Zhang N, Dong H, Yao L . Impairment and compensation coexist in amnestic MCI default mode network. Neuroimage. 2009; 50(1):48-55. DOI: 10.1016/j.neuroimage.2009.12.025. View

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

Park J, Na H, Kim S, Kim H, Kim H, Seo S . Robust Identification of Alzheimer's Disease subtypes based on cortical atrophy patterns. Sci Rep. 2017; 7:43270. PMC: 5343676. DOI: 10.1038/srep43270. View

Scheltens P, van de Pol L . Impact commentaries. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 2012; 83(11):1038-40. DOI: 10.1136/jnnp-2012-302562. View

Spaniol J, Davidson P, Kim A, Han H, Moscovitch M, Grady C . Event-related fMRI studies of episodic encoding and retrieval: meta-analyses using activation likelihood estimation. Neuropsychologia. 2009; 47(8-9):1765-79. DOI: 10.1016/j.neuropsychologia.2009.02.028. View

Villain N, Fouquet M, Baron J, Mezenge F, Landeau B, De La Sayette V . Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain. 2010; 133(11):3301-14. PMC: 3291528. DOI: 10.1093/brain/awq203. View

Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-13. PMC: 2696350. DOI: 10.1002/ana.21610. View

La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazizene M . Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci. 2012; 32(46):16265-73. PMC: 6794030. DOI: 10.1523/JNEUROSCI.2170-12.2012. View

Pike K, Savage G, Villemagne V, Ng S, Moss S, Maruff P . Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130(Pt 11):2837-44. DOI: 10.1093/brain/awm238. View

10.

La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, Pelerin A . Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer's and semantic dementia-targeted networks. Neuron. 2014; 81(6):1417-1428. DOI: 10.1016/j.neuron.2014.01.026. View

11.

van Rossum I, Vos S, Handels R, Visser P . Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis. 2010; 20(3):881-91. DOI: 10.3233/JAD-2010-091606. View

12.

Topiwala A, Allan C, Valkanova V, Zsoldos E, Filippini N, Sexton C . Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017; 357:j2353. PMC: 5460586. DOI: 10.1136/bmj.j2353. View

13.

Bokde A, Karmann M, Born C, Teipel S, Omerovic M, Ewers M . Altered brain activation during a verbal working memory task in subjects with amnestic mild cognitive impairment. J Alzheimers Dis. 2010; 21(1):103-18. DOI: 10.3233/JAD-2010-091054. View

14.

Shaw L, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K . Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011; 121(5):597-609. PMC: 3175107. DOI: 10.1007/s00401-011-0808-0. View

15.

Stern Y . Cognitive reserve. Neuropsychologia. 2009; 47(10):2015-28. PMC: 2739591. DOI: 10.1016/j.neuropsychologia.2009.03.004. View

16.

Cabeza R, Ciaramelli E, Olson I, Moscovitch M . The parietal cortex and episodic memory: an attentional account. Nat Rev Neurosci. 2008; 9(8):613-25. PMC: 2692883. DOI: 10.1038/nrn2459. View

17.

Vemuri P, Wiste H, Weigand S, Shaw L, Trojanowski J, Weiner M . MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009; 73(4):294-301. PMC: 2715214. DOI: 10.1212/WNL.0b013e3181af79fb. View

18.

Sorg C, Riedl V, Muhlau M, Calhoun V, Eichele T, Laer L . Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007; 104(47):18760-5. PMC: 2141850. DOI: 10.1073/pnas.0708803104. View

19.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

20.

Bai F, Zhang Z, Watson D, Yu H, Shi Y, Yuan Y . Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment. Biol Psychiatry. 2008; 65(11):951-8. DOI: 10.1016/j.biopsych.2008.10.017. View